Evidence map›Paper›PMID 21922167›Full record

ReviewCurrent urology reports2011

Emerging and novel therapeutic approaches in the treatment of male erectile dysfunction.

Eric Chung, Gerald B Brock

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current urology reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Canadian consensus algorithm for erectile rehabilitation following prostate cancer treatment.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2019
    Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Eric ChungDepartment of Urology, Princess Alexandra Hospital, Brisbane, QLD, Australia. ericchg@hotmail.com
Gerald B Brock

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the past few decades, a dramatic increase in our understanding of the pathophysiology of penile erection has occurred. The advent of phosphodiesterase type 5 inhibitors has revolutionized the treatment of erectile dysfunction (ED), while the introduction of modern penile prosthesis has almost completely replaced the need for vascular surgery. Despite the efficacy of current therapeutic options for ED, they are not without limitations and remain insufficient to address the growing patient population and various underlying medical conditions. Newer and novel ED therapies aspire to treat underlying microvascular abnormalities, prevent cavernosal fibrosis, promote endothelial revascularization, modulate neurohormonal pathways, and regenerate new penile tissue.

Indexed as

Penile ProsthesisCell- and Tissue-Based TherapyErectile DysfunctionGenetic TherapyHumansMalePenile ErectionPhosphodiesterase InhibitorsTissue EngineeringTreatment OutcomePhosphodiesterase Inhibitors

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.